

AK

PTO/SB/21 (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/645,471	
	Filing Date	August 20, 2003	
	First Named Inventor	Scot W. EBBINGHAUS	
	Art Unit	1645	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	8	Attorney Docket Number	532232000500

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Form 1449, 2 pages (in duplicate) (21) References Return Postcard
<div>Remarks</div> <p><b>CUSTOMER NO. 25225</b></p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Bruce D. Grant - 47,608
Signature	
Date	May 5, 2004


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: May 5, 2004	Signature:  (Rhea Amid)



PATENT  
Docket No. 532232000500

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on May 5, 2004.

  
Rhea Amid

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Scot W. EBBINGHAUS et al.

Serial No.: 10/645,471

Filing Date: August 20, 2003

For: METHODS FOR REGULATING  
TRANSCRIPTION BY TARGETING  
QUADRUPLEX DNA

Examiner: Not Yet Assigned

Group Art Unit: 1645

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Applicants respectfully request the Examiner to make note of related U.S. Patent Application Serial No. 10/407,449, filed April 4, 2003.

sd-176551

05/10/2004 TBESHAI 00000050 031952 10645471

01 FC:1806 180.00 DA

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 532232000500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: May 5, 2004

Respectfully submitted,

By: 

Bruce Grant  
Registration No. 47,608

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-7962  
Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION 	Docket Number 532232000500	Application Number 10/645,471
	Applicant Scot W. EBBINGHAUS et al.	
	Filing Date August 20, 2003	Group Art Unit 1645
	Mailing Date May <u>5</u> , 2004	

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	1.	Anantha et al., Biochemistry 37(9):2709-2714 (1998)
	2.	Cohen et al., J Biol Chem 272:2901-2913 (1997)
	3.	Datta et al., JACS 123:9612-9619 (2001)
	4.	Ewulonu et al., Proc Natl Acad Sci 88:4675 (1991)
	5.	Han et al., Nucl. Acids Res. 27:537-542 (1999)
	6.	He et al., Science 281:1509-1512 (1998)
	7.	Hurley et al., Pharmacology & Therapeutics 85:141-158 (2000)
	8.	Hurley, Nature Rev. Cancer 2:188-200 (2002)
	9.	Jin & Pike, Mol. Endocrinol. 10:196-205 (1996)
	10.	Marathias and Bolton, Biochemistry 38:4355-4364 (1999)
	11.	Matsugami et al., J. Mol. Biol. 313:255-269 (2001)
	12.	Matsugami et al., J. Biol. Chem. 278(30):28147-28153 (2003)
	13.	Postel et al., Mol. Cell. Biol. 9:5123-5133 (1989)
	14.	Postel, J. Biol. Chem. 274:22821-22829 (1999)
	15.	Ren et al., Biochemistry 38:16067-16075 (1999)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 532232000500	Application Number 10/645,471
INFORMATION DISCLOSURE CITATION IN AN APPLICATION 		Applicant Scot W. EBBINGHAUS et al.	
		Filing Date August 20, 2003	Group Art Unit 1645
		Mailing Date May <u>5</u> , 2004	
16.	Rustighi et al., Biochem. Biophys. Res. Comm. 265:439-447 (1999)		
17.	Rustighi et al., Biochemistry 41:1229-1240 (2002)		
18.	Shin-ya et al., J. Am. Chem. Soc. 123:1262 (2001)		
19.	Simonsson et al., Nucleic Acids Research 26(5):1167-1172 (1998)		
20.	Tone et al., J Immunology 165:286-91 (2000)		
21.	Weitzmann et al., J. Biol. Chem. 271:20958-20964 (1996)		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			